Nutex Health (NASDAQ:NUTX) Rating Increased to Strong-Buy at Zacks Research

Nutex Health (NASDAQ:NUTX) was upgraded by equities research analysts at Zacks Research from a “hold” rating to a “strong-buy” rating in a research report issued on Monday,Zacks.com reports.

NUTX has been the subject of a number of other reports. B. Riley Financial began coverage on Nutex Health in a research note on Friday, June 26th. They set a “buy” rating and a $290.00 price target for the company. Lake Street Capital reaffirmed a “buy” rating and set a $310.00 price objective (up from $235.00) on shares of Nutex Health in a research report on Tuesday, August 11th. Weiss Ratings raised shares of Nutex Health from a “hold (c)” rating to a “hold (c+)” rating in a research report on Tuesday, July 28th. Finally, Wall Street Zen lowered shares of Nutex Health from a “strong-buy” rating to a “buy” rating in a research note on Monday, July 20th. One investment analyst has rated the stock with a Strong Buy rating, two have assigned a Buy rating and one has assigned a Hold rating to the company’s stock. According to MarketBeat.com, the stock currently has a consensus rating of “Buy” and a consensus target price of $300.00.

Nutex Health Stock Performance

Shares of NUTX opened at $188.10 on Monday. The company has a market capitalization of $1.29 billion, a PE ratio of 7.39 and a beta of 0.24. The company has a debt-to-equity ratio of 0.59, a quick ratio of 4.96 and a current ratio of 5.00. The company’s 50 day moving average price is $168.99 and its 200 day moving average price is $131.92. Nutex Health has a 52 week low of $77.21 and a 52 week high of $204.00.

Nutex Health (NASDAQ:NUTX) last issued its earnings results on Thursday, August 6th. The company reported $9.38 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $4.95 by $4.43. Nutex Health had a net margin of 21.25% and a return on equity of 39.74%. The company had revenue of $210.75 million during the quarter, compared to analyst estimates of $215.03 million. Research analysts expect that Nutex Health will post 30.11 EPS for the current fiscal year.

Institutional Investors Weigh In On Nutex Health

Several hedge funds have recently made changes to their positions in the stock. Kilter Group LLC bought a new position in Nutex Health during the second quarter valued at about $27,000. Allworth Financial LP bought a new stake in shares of Nutex Health during the second quarter valued at approximately $35,000. Islay Capital Management LLC acquired a new position in shares of Nutex Health in the fourth quarter valued at $34,000. BNP Paribas Financial Markets lifted its position in Nutex Health by 966.7% in the second quarter. BNP Paribas Financial Markets now owns 320 shares of the company’s stock worth $40,000 after purchasing an additional 290 shares during the period. Finally, Royal Bank of Canada increased its holdings in Nutex Health by 752.4% in the 4th quarter. Royal Bank of Canada now owns 358 shares of the company’s stock valued at $59,000 after buying an additional 316 shares during the period. Institutional investors own 5.32% of the company’s stock.

About Nutex Health

Nutex Health, Inc (NASDAQ: NUTX) is an integrated outpatient healthcare services company based in San Antonio, Texas. The company focuses on delivering a range of ambulatory care solutions, including urgent care, telemedicine, medical imaging, teleradiology, weight‐loss services and behavioral health support. By combining in‐person clinics with virtual care capabilities, Nutex Health aims to provide patients with accessible, cost‐effective treatment options outside traditional hospital settings.

The company’s urgent care network operates through both standalone and retail‐anchored centers, offering treatment for non‐life‐threatening injuries and illnesses, preventive screenings and basic primary care.